News | October 20, 2022
Lupin to acquire two inhalation brands from Sunovion for US$75 million
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Subscribe To Our Newsletter & Stay Updated
